FindTrial
Sign In

Rezvilutamide

DRUG9 trials

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Jianbin Bi, Peking University First Hospital, The First Affiliated Hospital of Xiamen University

Conditions

Biochemical RecurrenceChemotherapy EffectHigh Risk Prostate CancerHormone Sensitive Prostate CancerIntense Endocrine TherapyLocally Advanced Prostate CancerMetastatic Hormone-Sensitive Prostate CancerMetastatic Prostate Cancer

Phase 1

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Not yet recruitingNCT07407283
Jiangsu HengRui Medicine Co., Ltd.Prostate Cancer
Start: 2026-03-01End: 2028-04-01Target: 100Updated: 2026-02-12

Phase 2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
RecruitingNCT05406999
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHigh Risk Prostate Cancer, Intense Endocrine Therapy, Locally Advanced Prostate Cancer +1
Start: 2020-02-01End: 2030-06-30Target: 900Updated: 2022-08-16
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
RecruitingNCT05753566
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBiochemical Recurrence, Prostate Cancer
Start: 2023-03-31End: 2028-03-31Target: 96Updated: 2023-03-06
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Not yet recruitingNCT06134271
Jianbin BiMetastatic Hormone-Sensitive Prostate Cancer
Start: 2023-11-15End: 2026-04-30Target: 160Updated: 2023-11-18
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
RecruitingNCT06305832
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBiochemical Recurrence, Prostate Cancer
Start: 2023-09-07End: 2028-03-31Target: 102Updated: 2024-03-12
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
RecruitingNCT06348264
Peking University First HospitalSalivary Gland Neoplasm Duct
Start: 2024-10-10End: 2031-03-30Target: 37Updated: 2025-09-23
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
RecruitingNCT06387056
The First Affiliated Hospital of Xiamen UniversityLocally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
Start: 2024-04-01End: 2029-04-01Target: 40Updated: 2024-04-26

Phase 3

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
RecruitingNCT05983783
The First Affiliated Hospital with Nanjing Medical UniversityChemotherapy Effect, Hormone Sensitive Prostate Cancer, Metastatic Prostate Cancer
Start: 2023-08-01End: 2027-12-31Target: 200Updated: 2023-08-09

Unknown Phase

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
CompletedNCT07428642
First Affiliated Hospital of Wenzhou Medical UniversityMetastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
Start: 2020-09-01End: 2025-12-03Updated: 2026-03-18

Related Papers

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.
2025-03-101 citations
Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.
Journal of Clinical Oncology2024-01-29
A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery
Frontiers in Oncology2023-01-13